Yahong Pharmaceutical was selected as one of the top 30 innovative small molecule drug companies in China

Shanghai, September 27, 2021/PRNewswire/ - Yahong Medicine has recently announced that it has been selected as the "2020 China Primary School" at the "2020 China Top 100 Innovative Biopharmaceutical Enterprises Series" conference hosted by Minai.

Yahong Pharmaceutical was selected as one of the top 30 innovative small molecule drug companies in China

The list is guided by the ability to implement biomedical innovation achievements, based on the "Enterprise Innovation Capability Evaluation Index System" of the Ministry of Science and Technology, and based on the characteristics of China's biomedical industry, with "innovation input", "innovation achievements", and "intellectual property rights" "Innovation-driven" four dimensions and 11 indicators constitute the innovation evaluation system of China's biomedical companies, and 100 companies with medical innovation capabilities in China have been selected

The selection of Yahong Pharmaceutical this time also proves its innovative strength in the specialty field

Adhering to the mission of "improving human health and making life more dignified", Yahong Pharmaceutical will continue to strengthen its independent research and development capabilities in the future, actively explore an integrated model of diagnosis and treatment, and provide patients with overall solutions

About Yahong Medicine

Established in March 2010, Yahong Pharmaceutical is a global innovative drug company focusing on genitourinary system tumors and other major diseases

The company insists on taking innovative technologies and products as its core driving force, and by building its own R&D platform and core technology, it deeply explores the mechanism of drug action, and efficiently screens and evaluates drug candidates

At the same time, through independent research and development and strategic cooperation, Yahong has carried out in-depth layout of product pipelines around genitourinary system diseases, paid close attention to the technological frontiers and treatment development trends in this field, insight and mining unmet clinical needs, and forward-looking products Planning and life cycle management, to create a superior product portfolio from disease diagnosis to treatment, so as to benefit more Chinese and global patients

Source: Asieris